Company

Tune Therapeutics, Inc.

Tune Therapeutics develops gene and cell therapies using epigenetic programming.

About

Founded in 2020 and based in North Carolina, US, Tune Therapeutics develops treatments for genetic diseases and cancers using its TEMPO platform to adjust gene expression. In January 2025, it raised USD 175 million in series B funding led by returning investor New Enterprise Associates, with Yosemite Management, Regeneron Ventures and Hevolution Foundation. The funding was intended to support development of its medical pipeline.

2Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in